Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMorgan Advanced Materials Regulatory News (MGAM)

Share Price Information for Morgan Advanced Materials (MGAM)

Share Price is delayed by 15 minutes
Get Live Data
229.00    1.00 (0.44%)
Bid:
228.50
Ask:
229.50
Spread: 1.00 (0.438%)
Market Cap: £632.99m
MGAM Live PriceLast checked at - London Stock Exchange

Intraday Morgan Advanced Materials Share Chart

Strategy Update

4 Dec 2025 07:00

RNS Number : 1624K
Morgan Advanced Materials PLC
04 December 2025
 

Press Release

Morgan Advanced Materials plc

4 December 2025

Strategy Update

Unlocking our potential

Morgan Advanced Materials plc, the global leader in advanced ceramics and carbon systems for technologically demanding applications, is today holding a Strategy Update in London. Participation in the event is by invitation only for institutional analysts and investors.

Damien Caby, Chief Executive Officer and Richard Armitage, Chief Financial Officer will host the event. They will present Morgan's strategy for sustainable growth, focussing on:

Transforming our operational effectiveness to turnaround underperforming sites and improve our supply chain effectiveness

Driving stronger growth by focusing on our right to win to enhance our value proposition, strengthening partnerships, and expanding in the right areas to gain share

Maximising our portfolio through partnerships, divestments and bolt-on M&A

They will also set out an updated financial framework and re‐iterate our capital allocation priorities:

Above Market Organic Revenue Growth. We expect to achieve growth in excess of GDP

Attractive Margins. We expect to achieve adjusted operating profit margin of 12% by 2028 with sustainable adjusted operating profit margins of between 12% and 14% beyond 2028

Delivering EPS Growth. Achieving sustained growth in adjusted Earnings per Share, ahead of organic revenue growth, driven by a combination of organic growth, margin accretion, shareholder returns and M&A

Sustaining ROIC. 17% ‐ 20% ROIC

Leverage Range. 1.0x to 1.5x, or up to 2.0x adjusted EBITDA post-acquisition, utilising our strong balance sheet to fund our organic growth, and then over time deploying excess capital to fund incremental M&A or additional shareholder returns as appropriate

Dividend Cover. Shareholder dividends maintained then growing with adjusted earnings at around 2.5x cover

We intend to pause our buy-back programme as part of our focus on balance sheet resilience. The programme will be paused after the completion of the second tranche, by which time we will have purchased £20m of shares.

No new information on current year trading will be shared at the event.

Damien Caby, Chief Executive Officer, commented:

"Morgan is an exciting innovative company with distinctive capabilities and competitive advantages that give us a decisive right to win across our diverse markets. However, we have not been delivering to our ambition or to our full potential. Much of this value can be achieved through more rigorous customer focus and portfolio management. I will set out today a clear strategy focussing on unlocking the Group's potential by focussing on transformation of operational effectiveness, driving stronger growth and the maximisation of portfolio value. This will help us improve the financial performance of the group on a more sustainable basis to deliver against a revised financial framework."

The presentation will be made available at www.morganadvancedmaterials.com at 2pm today, along with a recording of the presentation that will be made available following the event.

 

For further enquiries:

Richard Armitage, CFO

Morgan Advanced Materials

01753 837 000

Nicholas Frost, Investor Relations

 

 

 

 

Nina Coad

Brunswick

0207 404 5959

 

Important notice:

This announcement contains forward-looking statements. These statements have been made in good faith based on the information available up to the time of the approval of this announcement. No assurance can be given that these expectations will prove to have been correct. By their nature, forward-looking statements involve risks, uncertainties or assumptions that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. As such, undue reliance should not be placed on forward-looking statements.

The Directors undertake no obligation to update any forward-looking statements whether as a result of new information, future events or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDKXLFBELLZFBD
Date   Source Headline
26th Sep 202312:24 pmRNSDirector/PDMR Shareholding
16th Aug 202311:27 amRNSDirector/PDMR Shareholding
7th Aug 20235:24 pmRNSDirector/PDMR Shareholding
4th Aug 20237:00 amRNSHalf-Year Results for Period Ended 30 June 2023
13th Jul 20234:49 pmRNSDirector/PDMR Shareholding
5th Jul 20234:51 pmRNSDirector/PDMR Shareholding
29th Jun 20235:06 pmRNSResult of AGM
29th Jun 20237:00 amRNSH1 Trading Update
22nd Jun 202311:50 amRNSBlock listing Interim Review
31st May 20233:52 pmRNSDirector/PDMR Shareholding
26th May 20233:28 pmRNSNotice of Annual General Meeting 2023
24th May 20233:59 pmRNSDirector/PDMR Shareholding
11th May 202312:06 pmRNSDirector/PDMR Shareholding
11th May 202312:01 pmRNSDirector/PDMR Shareholding
11th May 202311:59 amRNSDirector/PDMR Shareholding
9th May 20235:59 pmRNSDirector/PDMR Shareholding
4th May 20235:28 pmRNSAnnual Report & Accounts 2022
3rd May 20235:38 pmRNSDirector/PDMR Shareholding
3rd May 20235:28 pmRNSDirector/PDMR Shareholding
28th Apr 20235:45 pmRNSInformation required by DTR 4.1
28th Apr 20237:00 amRNSFull-year results for the period ended 31 Dec 2022
13th Apr 20237:00 amRNSNotification of Full-Year Results
7th Feb 20237:00 amRNSUpdate on Trading and Cyber Security Incident
18th Jan 20237:00 amRNSAppointment of Chair Designate
10th Jan 20237:00 amRNSNotice of Cyber Security Incident
22nd Dec 202211:01 amRNSBlock listing Interim Review
16th Dec 20224:44 pmRNSHolding(s) in Company
6th Dec 20227:00 amRNSAccelerated Pension Contribution
6th Dec 20227:00 amRNSCapital Markets Event
23rd Nov 202210:01 amRNSDirector/PDMR Shareholding
15th Nov 20225:06 pmRNSDirector/PDMR Shareholding
10th Nov 20228:03 amRNSDirector Declaration
4th Nov 20227:00 amRNSTrading Update
17th Oct 20222:21 pmRNSDirector/PDMR Shareholding
26th Sep 202212:52 pmRNSDirector/PDMR Shareholding
26th Sep 202212:49 pmRNSDirector/PDMR Shareholding
29th Jul 20227:00 amRNSHalf-year results
15th Jun 20229:30 amRNSBlock listing Interim Review
1st Jun 202210:00 amRNSDirector/PDMR Shareholding
31st May 202210:06 amRNSDirector/PDMR Shareholding
24th May 20222:32 pmRNSDirector/PDMR Shareholding
16th May 20222:52 pmRNSDirector/PDMR Shareholding
5th May 20223:12 pmRNSDirectorate Change
5th May 20222:00 pmRNSResult of AGM
5th May 20227:00 amRNSQ1 trading update
3rd May 20222:45 pmRNSHolding in Company
14th Apr 20222:59 pmRNSHolding(s) in Company
30th Mar 20223:25 pmRNSAnnual Financial Report
28th Mar 202212:00 pmRNSHolding in Company
23rd Mar 202211:02 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.